Cancer Genetics — IPO Roadshow (October 2013)
37 slides from Cancer Genetics's IPO roadshow presentation, Oct 17, 2013
Slide 1: Empowering Personalized Cancer Treatment
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-191633 October 17, 2013 EM PO W ERI N G P ER SO N A L I Z ED C A N C ER T REA T M EN T CGIX (NASDAQ)
Slide 2: Forward-Looking Statement
Forward-Looking Statement All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Cancer Genetics, Inc. (The Company) products and services, along with other statements about the future expec
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing. We have filed a registration statement (including a preliminary prospectus) with
Slide 4: Offering Summary
Offering Summary Issuer Cancer Genetics, Inc. Exchange / Ticker NASDAQ / CGIX Offering Size $50,000,000 Over-Allotment 15% • Sales & Marketing Expansion • Mayo Joint Venture Use of Proceeds • Product Commercialization • General Working Capital Sole Book-Runner Aegis Capital Corp. Co-Managers Feltl &
Slide 5: Growth-Stage, Oncology-Focused, Personalized-Diagnostics Company
Growth-Stage, Oncology-Focused, Personalized-Diagnostics Company Established multi-year track record of top-line growth with improving margins Hybrid business model providing proprietary genomic products, clinical cancer testing and clinical trial services for biotechs and pharmas Portfolio of comme
Slide 6: Molecular Diagnostics are Changing our Understanding of Cancer
Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients Our unique focus & approach supports the entire cancer care continuum DIAGNOSIS PROGNOSIS THERANOSIS Use genomics to Assist in patient Personalize provide an accurate outcome and dis
Slide 7: CGI's Mission is to Personalize and Improve the Success Rate in Cancer Treatment
CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment Traditional Approach Our Approach: Personalized Medicine Phenotypic & Biomarkers and Physical Examination Companion Diagnostics Morphologic & Genomic Analysis & Pathological Analysis Proprietary Algorithms Large & Multi
Slide 8: Unique, Scalable and Multifaceted Business Model
Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution PROPRIETARY PRODUCTS CLINICAL SERVICES BIOPHARMA PARTNERSHIPS Proprietary molecular Differentiated and complete Biomarker and companion diagnostics & FISH probes disease-focused solutions diagnostic develo
Slide 9: Our Target Markets in Oncology Testing Comprise Over 610,000 New Lives Annually
Our Target Markets in Oncology Testing Comprise Over 610,000 New Lives Annually in the U.S. Hematological: Urogenital: Gynecological: Lymphoma, Leukemia, M. Myeloma Kidney, Bladder & Prostate Cervical, Endometrial & Ovarian 149,990 376,310 84,140 2013 Estimated New Cases 2013 Estimated New Cases 201
Slide 10: 5 Proprietary Diagnostic Products Commercially Launched & In Market
5 Proprietary Diagnostic Products Commercially Launched & In Market Research & Clinical Commercial Launch & Clinical Collaboration & Discovery Development Development Market Entry Validation Partners MatBA® - Chronic & Small Lymphocytic Leukemia MatBA® - Diffuse Large B-Cell Lymphoma MatBA® - Mantle
Slide 11: Case Numbers for Hematologic Cancers are Still Rising
Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs (US Only, per 100,000) 21.2 20.0 19.7 20.5 89 18.5 15.5 12.6 11.1 12 7.1 7.9 8.7 8.2 6.9 7.3 1 2 5 5.6 6.2 100 80 60 30 2 1975 1985 1995 200
Slide 12: MatBA-CLL/SLL Array-CGH Improves Risk Stratification & Outcome Prediction
MatBA ®-CLL/SLLArray-CGH Improves Risk Stratification & Outcome Prediction Impact on therapy selection & FISH clinical management of CLL (Current Method) (CGI Method) patients. Favorable 38% of cases in our study have Intermediate 38% a favorable prognosis falling Unfavorable under "watch & wait" ap
Slide 13: MatBA Can Group Patients Into Risk Groups and Prognostication Classes
MatBA® Can Group Patients Into Risk Groups and Prognostication Classes MatBA®- CLL / SLL is a diagnostic tool and Time to First Treatment (TTFT) prognostic indicator for patient stratification and improved patient management Being actively used in clinical care, in clinical trials and in validation
Slide 14: UroGenRA-Kidney Can Help Guide Treatment Selection
UroGenRA™-Kidney Can Help Decide if Partial Kidney Removal Is Required and Guide Treatment Selection PROBLEM SOLUTION Men and women with renal masses UroGenRA™ is designed to detect genomic often undergo unnecessary aberrations in a single assay in percutaneous nephrectomy for accurate diagnosis nee
Slide 15: FHACT - A New Genomic Aid in Cervical Cancer Screening
FHACT™- A New Genomic Aid In The Screening & Management Of Cervical Cancer Cervical cancer effects nearly 500,000 women annually with nearly 80% in developing countries. HPV+ 90% Regress Abnormal 10% Progress to Normal Grade Cervical to Higher Grade Decreased Risk for Cancer Lesions Increased Risk f
Slide 16: IP Position and Detailed Global Strategy
IP Position and Detailed Global Strategy Tool for Diagnosis and Prognosis of Mature B-Cell Methods of Analyzing Chromosomal Translocations Neoplasms Using Fluorescence In Situ Hybridization (FISH) US Issued Patent 13/475,034 US Issued Patent 7,585,964 US Issued Patent 7,964,345 Panel for the Detecti
Slide 17: Large, Targeted Market Opportunities
Large, Targeted Market Opportunities Target Markets Commercialization Strategy Collaborate to create and validate microarrays Universities and Research Centers and other proprietary products Accelerate launch of large scale studies Continue to growing sales force that calls on Community Hospitals ho
Slide 18: Unique Service Offering Developed to Enable Community Hospitals
Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally Delivers better outcomes to community hospitals and Expanding & Developing Cancer Care laboratories is a Top Priority for Hospital CEOs & CFOs Enables community hospitals to bring “sta
Slide 19: Clinical Trial Services Showing Strong Growth and Robust Pipeline
Clinical Trial Services Showing Strong Growth and Robust Pipeline ONCOLOGY DRUGS ASSOCIATED GROWTH IN CGI’s DIRECT BILL WITH BIOMARKER(S) CLIENTS ($000) Source: Company Analysis and Management Estimates Well-Positioned for Use in Clinical Trials & Companion Diagnostic Programs 2013 Cancer Genetics,
Slide 20: Gilead is Currently Using a Comprehensive Panel of CGI Services
Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for Hematologic Cancers Highlights Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring Improved patient profiling will result i
Slide 21: Collaborations with Premier Cancer Research Institutions
Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption Research Collaboration/ Clinical Partnership Licensing Services Highlights Kidney Cancer, DLBCL, MCL & FL Joint Venture Focused on Oncology & Next Generation Sequencing Cervical Cancer
Slide 22: Well-Positioned and Growing Internationally
Well-Positioned and Growing Internationally Including in Emerging Economies International revenue comes from sale of oncology products (DNA-FISH probes, arrays) and services to emerging economies Expect exposure to increase to emerging economies through strong partnerships with Kamineni Life Science
Slide 23: Roche Partnership
Roche Partnership Expanding Market Presence Internationally CGI will be providing genomic and biomarker testing services to 14 countries in Central America and the Caribbean. Highlights CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin America) Roch
Slide 24: Mayo Clinic Joint Venture
Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics Next Generation Sequencing in Oncology Highlights JV to develop clinical diagnostic products and services on NGS platform(s) for select cancers Select three initial projects in key oncology categories by the SRC (Scientific Revie
Slide 25: Strong History of Growth
Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013thru 6 mos) Total Revenue ($Mn) Clinical Volume (Tests Processed) 6,610 $4.30 5,115 $3.02 $3.05 $2.52 3,622 3,146 $1.67 2,321 2009 2010 2011 2012 1H-2013 2009 2010 2011 2012 1H-2013 Trailing 12 Months Revenue is $5.4 Mn 2013 C
Slide 26: Strong History of Growth - Revenue & Clinical Volume Trends
Strong History of Growth - Revenue & Clinical Volume Trends (Quarterly Comparison 2012 vs. 2013) Total Revenue ($000) Clinical Volume (Tests Processed) $1,832 3,204 60% 97% 46% 19% $1,218 $1,148 1,911 1,610 1,623 $835 Grants* Grants* 2012 2013 2012 2013 2012 2013 2012 2013 st nd st nd 1 Quarter 2 Qu
Slide 27: Summary Statement of Operations
Summary Statement of Operations (2009-2013 thru 6 mos) Income Statement Item 2009 2010 2011 2012 1H-2013 Revenue $1,666 $2,522 $3,019 $4,302 $3,050 Gross Profit (866) (995) (98) 373 701 Gross Margin (%) (52%) (39%) (3%) 9% 23% Research & Development (R&D) 1,336 1,167 2,074 2,112 951 Sales & Marketin
Slide 28: Summary Statement of Operations
Summary Statement of Operations (Quarterly & First Half Comparisons 2012 vs. 2013) Income Statement Item Q2 2012 Q2 2013 1H 2012 1H 2013 Revenue $1,148 $1,832 60% $1,983 $3,050 54% Gross Profit 62 553 +100% 74 701 +100% Gross Margin (%) 5% 30% +100% 4% 23% +100% Research & Development (R&D) 527 456
Slide 29: Summary Balance Sheet
Summary Balance Sheet Actual 06/30/13 Pro Forma (A) Cash & Cash $12,668 $1,941 Equivalents Total Assets 6,456 17,038 Total Liabilities 13,325 9,681 Stockholders’ (Deficit) Equity (6,869) 7,357 $ in thousands (A) Pro Forma basis gives effect to (i) the receipt of net proceeds of approximately $13.3 M
Slide 30: Consistent Focus on Gross Profit Improvements
Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India Gross Profit Margin Highlights of Initiatives 800 23% Manufacturing in India (Probes) 600 Increased automation 400 9% Process improvement and 200 innovation 0 Capacity utilization (52%) (3%) 2012 1H-
Slide 31: Multiple Customer Types Provide Diversified Revenue Mix
Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place Payor Revenue Mix 2013 (1H, 2013) Selected Payors 3% 13% 57 million covered lives through multiple payors: 1H, 2013 27% 57% Direct Bill Customer Types Academic Biotechs Cancer Facilities Reimbursement Based D
Slide 32: Experienced and Focused Management and Boards
Experienced and Focused Management and Boards Board of Directors Raju Chaganti, Ph.D. Keith Brownlie John Pappajohn Franklyn Prendergast, M.D., Ph.D. Panna Sharma Edmund Cannon Andrew Pecora, M.D. The Honorable Tommy G. Thompson Officers & Management Team Scientific Advisory Board Andrea Califano, P
Slide 33: Strong, Commercially-Focused News Flow & Consistent Achievement of Milestones
Strong, Commercially-Focused News Flow & Consistent Achievement of Milestones Expected in Coming Quarters Recent Accomplishments Upcoming Milestones & Value Drivers Accelerating market traction – over 50% quarter to quarter growth in 2013 Increasing covered lives market access through additional and
Slide 34: For further information, please contact us
For further information, please contact us at ir@cancergenetics.com Cancer Genetics, Inc. Meadows Office Complex 201 Route 17 North Rutherford, NJ 07070 (201) 528-9200 www.cancergenetics.com
Slide 35: Appendix
Appendix
Slide 36: Summary Capitalization Table
Summary Capitalization Table Pro Forma CGIX Cap Table 06/30/2013 06/30/2013 Common Stock 4,316,691 5,921,691 Warrants* – Average Exercise Price of $12.15 1,926,477 1,926,477 Options – Average Exercise Price of $7.61 507,610 507,610 Total – Fully Diluted 6,750,778 8,355,778 Excludes 450,390: 440,390
Slide 37: Expanding Proprietary Capabilities Across Full Range of DNA Detection Methodologies
Expanding Proprietary Capabilities Across Full Range of DNA Detection Methodologies DNA-FISH Probe • Low Resolution (~1-2Mb) • Mid-High Market Maturity • Value: High in established markets and growing in emerging markets Existing CGI Capabilities DNA Microarray • High Resolution (~1-2kb) • Low-Mid M